Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, Kim YS, Peterson BS. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics. 1998;102(1 Pt 1):14–9.

Article  CAS  PubMed  Google Scholar 

Cutler D, Murphy T, Gilmour J, Heyman I. The quality of life of young people with Tourette syndrome. Child Care Health Dev. 2009;35(4):496–504.

Article  CAS  PubMed  Google Scholar 

Piacentini J, Woods DW, Scahill L, Wilhelm S, Peterson AL, Chang S, Ginsburg GS, Deckersbach T, Dziura J, Levi-Pearl S, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilhelm S, Peterson AL, Piacentini J, Woods DW, Deckersbach T, Sukhodolsky DG, Chang S, Liu H, Dziura J, Walkup JT, et al. Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry. 2012;69(8):795–803.

Article  PubMed  PubMed Central  Google Scholar 

Farag M, Stern JS, Simmons H, Robertson MM. Serial pharmacological prescribing practices for tic management in Tourette syndrome. Human Psychopharmacol. 2015;30(6):435–41.

Article  CAS  Google Scholar 

Besag FM, Vasey MJ. Pharmacological treatment for Tourette syndrome in children and adults: what is the quality of the evidence? A systematic review. J Psychopharmacol. 2021;35(9):1037–61.

Article  CAS  PubMed  Google Scholar 

Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979;136(3):317–20.

Article  CAS  PubMed  Google Scholar 

Scahill L, Erenberg G, Berlin CM Jr., Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3(2):192–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu ZS, Cui YH, Sun D, Lu Q, Jiang YW, Jiang L, Wang JQ, Luo R, Fang F, Zhou SZ, et al. Current status, diagnosis, and treatment recommendation for Tic disorders in China. Front Psychiatry. 2020;11:774.

PubMed  PubMed Central  Google Scholar 

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381–9.

Article  CAS  PubMed  Google Scholar 

Greenaway M. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2009;18(3):250–60.

PubMed  PubMed Central  Google Scholar 

Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2013;15(3):217–33.

Article  PubMed  Google Scholar 

Janik P, Szejko N. Aripiprazole in treatment of Gilles De La Tourette syndrome—new therapeutic option. Neurol Neurochir Pol. 2018;52(1):84–7.

Article  PubMed  Google Scholar 

Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, Kim BN, Cho SC. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry. 2013;74(8):e772–780.

Article  CAS  PubMed  Google Scholar 

Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, van Beek A, Nyilas M, Carson W, Kurlan R, Randomized. Double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27(9):771–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cothros N, Martino D, McMorris C, Stewart D, Tehrani A, Pringsheim T. Prescriptions for alpha agonists and antipsychotics in children and youth with tic disorders: a pharmacoepidemiologic study. Tremor Other Hyperkinetic Mov. 2019. https://doi.org/10.7916/tohm.v0.645.

Article  Google Scholar 

Hamamoto Y, Fujio M, Nonaka M, Matsuda N, Kono T, Kano Y. Expert consensus on pharmacotherapy for tic disorders in Japan. Brain Dev. 2019;41(6):501–6.

Article  PubMed  Google Scholar 

Yang C, Yi Q, Zhang L, Cui H, Mao J. Safety of aripiprazole for tics in children and adolescents: a systematic review and meta-analysis. Medicine. 2019;98(22):e15816.

Article  PubMed  PubMed Central  Google Scholar 

Roessner V, Eichele H, Stern JS, Skov L, Rizzo R, Debes NM, Nagy P, Cavanna AE, Termine C, Ganos C, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):425–41.

Article  PubMed  Google Scholar 

Tokyo J. Otsuka Pharmaceutical Co., Ltd.: Abilify® (aripiprazole): Full Prescribing Information. 2020.

Yoo HK, Lee JS, Paik KW, Choi SH, Yoon SJ, Kim JE, Hong JP. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. Eur Child Adolesc Psychiatry. 2011;20(3):127–35.

Article  PubMed  Google Scholar 

Rizzo R, Eddy CM, Calí P, Gulisano M, Cavanna AE. Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome. Pediatr Neurol. 2012;47(6):419–22.

Article  PubMed  Google Scholar 

Wenzel C, Kleimann A, Bokemeyer S, Müller-Vahl KR. Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol. 2012;32(4):548–50.

Article  CAS  PubMed  Google Scholar 

Cox JH, Seri S, Cavanna AE. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders. Pediatr Health Med Ther. 2016;7:57–64.

Article  CAS  Google Scholar 

Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, Martino D, Müller-Vahl K, Woods DW, Robinson M, et al. Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):907–15.

Article  PubMed  PubMed Central  Google Scholar 

Alessandrini E, Brako F, Scarpa M, Lupo M, Bonifazi D, Pignataro V, Cavallo M, Cullufe O, Enache C, Nafria B, et al. Children’s preferences for oral dosage forms and their involvement in formulation research via EPTRI (European paediatric translational research infrastructure). Pharmaceutics. 2021;13(5):730.

Article  PubMed  PubMed Central  Google Scholar 

Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989;28(4):566–73.

Article  CAS  PubMed  Google Scholar 

Leckman J, Sweet RD. Tourette’s syndrome and Tic disorders: clinical understanding and treatment. Neurology. 1988;38(12):1902–1902.

Article  Google Scholar 

Jeon S, Walkup JT, Woods DW, Peterson A, Piacentini J, Wilhelm S, Katsovich L, McGuire JF, Dziura J, Scahill L. Detecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods. Contemp Clin Trials. 2013;36(2):414–20.

Article  PubMed  PubMed Central  Google Scholar 

Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45(5):596–603.

Article  PubMed  Google Scholar 

Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry Revue Canadienne de Psychiatrie. 2012;57(3):133–43.

Article  PubMed  Google Scholar 

Todd RD. Neural development is regulated by classical neurotransmitters: dopamine D2 receptor stimulation enhances neurite outgrowth. Biol Psychiatry. 1992;31(8):794–807.

Article  CAS